Cunningham Bounds Investigates Cases of Eye Damage Linked to Elmiron®
Mobile, Ala. – The personal injury law firm of Cunningham Bounds is investigating potential lawsuits on behalf of individuals who have taken Elmiron® and experienced eye damage. Elmiron® (also known as “pentosan polysulfate sodium” or “PPS”) is a prescription medication and is the only FDA approved oral drug used to treat bladder pain or discomfort associated with interstitial cystitis (IC).
Recent studies show that using Elmiron® may damage the retina, leading to “vision threatening toxicity.” Its use may cause irreparable damage in the macula – the retina’s central area that delivers clear, crisp central vision – leading to irreversible vision loss and even blindness.
Signs Elmiron® may have caused eye damage include:
- Difficulty reading
- Difficulty adapting to dim lighting
- Blurred vision (often centrally in the field of vision)
- Dark spots in center of vision
- Straight lines appearing curved or squiggly
- Less vivid colors
According the American Academy of Ophthalmology, the damage caused by the drug masquerades as age-related macular degeneration or pattern dystrophy; making diagnosis difficult for many patients. Researchers only recently made the connection between Elmiron® and its danger to the retina.
If you have taken, or are taking, Elmiron® you could be at risk. For more information, visit our website at www.cunninghambounds.com, call us at 251.471.6191 or toll free at 251.472.6191.
We will evaluate your potential case, free of charge.
The law firm of Cunningham Bounds, LLC, founded in 1958, is based in Mobile, Alabama and has been representing plaintiffs for over 60 years. Today the firm continues its tradition of representing victims in cases involving catastrophic personal injury, industrial accidents, defective products, truck and automobile accidents, and medical malpractice. The firm also has expertise in business litigation, complex litigation, and national and state class action litigation involving defective products and consumer fraud.